Navigation Links
If You Bought ExtenZe, You Might Receive Money and Benefits from a Class Action Settlement.
Date:10/27/2010

SANTA MONICA, Calif., Oct. 27 /PRNewswire/ -- The following statement is being issued by Milstein, Adelman & Kreger, LLP and Wasserman, Comden, Casselman & Esensten, LLP regarding the ExtenZe class action settlement.

A proposed class action settlement has been reached involving the manufacturer of a male enhancement product called ExtenZe.  The case is known as Williams, et al. v. Biotab Nutraceuticals, Inc., et al., Case No. BC414808 (consolidated with BC415918) ("the Action") Los Angeles County Superior Court.  The lawsuit alleges that Biotab Nutraceuticals, Inc. ("Biotab"), the manufacturer of ExtenZe, and certain individuals made false claims in certain marketing, promotional and advertising materials saying that ExtenZe would increase penis size.  Biotab and the other defendants deny they did anything wrong.

Who is a Class Member?  The Class consists of all persons who purchased ExtenZe in the United States between May 29, 2005 and October 25, 2010.  

What is this case about? If the settlement is approved, Defendants will be enjoined from making certain representations about their product, including being prevented from claiming that it will make the penis larger absent independent scientific substantiation. Further, a cash fund of $6,000,000 will be set up along with an additional $6,000,000 in retail value of ExtenZe NASCAR merchandise. A full description of the benefits can be found on www.extenzesettlement.com. Class Members who submit a valid Claim Form may choose a refund on the previously purchased product or choose up to $176.94 worth of ExtenZe NASCAR racing apparel. Full details of all the benefits are found on www.extenzesettlement.com.

What are my options?  You have decisions to make and you must make them now.  Stay in the class. In order to receive a cash reimbursement or racing apparel, you must obtain and submit a valid Claim Form. Claim Forms can be obtained by calling the 800 number or visiting www.extenzesettlement.com. The deadline to file your claim is April 15, 2011. If you stay in the class, you give up any rights to sue Defendants about the same legal claims in this lawsuit and you will be bound by the Court's decisions. The Claim Form will include instructions for the submission process.  Settlement Class Members may submit Claim Forms online, or by mail to the Settlement Administrator at the address below.

Get out of the lawsuit.  If you ask to be excluded, you will NOT receive money or benefits if the Settlement is approved, but you keep any rights to sue Defendants separately about the same legal claims in this lawsuit.  If you intend to bring your own lawsuit against Defendants, you should exclude yourself from the Class.  If you want to exclude yourself from the class action, you must formally request to exclude yourself by sending a letter to: Williams, et al. v. Biotab Nutraceuticals, Inc. EXCLUSIONS: c/o The Garden City Group, Inc., P.O. Box 9478, Dublin, OH 43017-4578.  You must sign and date the letter, which must be postmarked on or before January 11, 2011.

Who represents you?  As a member of the Class, you will be represented by Wasserman, Comden, Casselman & Esensten, LLP, 5567 Rededa Blvd., Ste. 330, Tarzana CA 91357-7033; Milstein Adelman & Kreger, LLP, 2800 Donald Douglas Loop North, Santa Monica, CA 90405; the Law Office of Bruce B. Whitman; Statman, Harris & Eyrich, LLC; and the Newport Trial Group, LLC. You will not be charged a fee for their services in this case.  However, if you want to be represented by your own lawyer, you may hire one at your own expense.

The Court will hold a Final Approval Hearing on March 30, 2011 in Department 28 of Los Angeles County Superior Court to consider the Settlement and Class Counsel's request for attorneys' fees, plus expenses.  You don't have to attend the Hearing.  

For more information.  This notice is only a summary.  For more detailed information, please call 800-961-6428, visit www.extenzesettlement.com, or write to Williams, et al. v. Biotab Nutraceuticals, Inc: c/o The Garden City Group, Inc. P.O. Box 9478 Dublin, OH 43017-4578.


'/>"/>
SOURCE Wasserman, Comden, Casselman & Esensten, LLP and Milstein, Adelman & Kreger, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
2. St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy
3. Aching Back? Cholesterol Medication Might Help
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
(Date:3/27/2017)... , March 27, 2017 ... to better understand Bayer and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... in Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics ... power plant water and steam. , Chlorides and sulfates cause pitting and stress ... extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... ... 28, 2017 , ... Prominant bariatric surgeon and well-known weight-loss ... offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon is ... already comprehensive list of weight-loss services. Dr. Liu is proud to announce ...
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
Breaking Medicine News(10 mins):